Back to search results

NPC-1 for Alzheimer's Pathology

This study is testing a natural product combination called NPC-1, which includes parthenolide and ipriflavone. It's for people aged 55 and older who have subjective cognitive decline (memory concerns), mild cognitive impairment (MCI), or Alzheimer's disease. The main goal is to see if NPC-1 is safe, tolerable, and how it affects certain markers in the blood related to Alzheimer's disease, such as p-tau217, glial fibrillary acidic protein, and neurofilament light chain, after 6 months. We don't know the current recruitment status for this study.

Study design
This is an early phase, open-label study, meaning everyone knows what treatment they are receiving. It will involve about 40 participants and does not compare NPC-1 to another treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures blood markers at 6 months, which suggests a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07236190

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Recruiting
PHASE2Ages 55+InterventionalTreatment
Massachusetts General Hospital
~40 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:natural product combination-1 (NPC1)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
plasma p-tau217
Measured over 6 months
+4 more outcomes measured

Conditions

Alzheimer Disease
Mild Cognitive Impairment (MCI)
Subjective Cognitive Decline (SCD)

Explore related trials

Alzheimer's DiseaseMild cognitive disorderSubjective Cognitive DeclineAbeta42/40 ratioAmyloid P componentp-tau217

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Gene Bowman, ND, MPH · PRINCIPAL_INVESTIGATOR · Harvard/Massachusetts General Hospital

Who to contact

Gene Bowman, N.D., M.P.H.
[email protected]
857-282-5197
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab
b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted)
c. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs
d. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit
e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded 14. Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator 15. Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator.

What this trial measures

  • plasma p-tau2176 months

    Intra-individual changes from pre-treatment observational period to post-treatment interventional period

  • plasma glial fibrillary acidic protein6 months

    Intraindividual changes

  • plasma neurofilament light chain6 months

    Intra-individual changes

  • plasma abeta42 / abeta406 months

    Intraindividual changes

  • Safety and Tolerability of NPC1Baseline through 6 months

    Assessment of Adverse Events Related to NPC1 Treatment